Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy

AIDS

Volumn 28, Issue 16, 2014, Pages 2407-2415

  Galli, Laura ^a   Spagnuolo, Vincenzo ^a,b   Poli, Andrea ^a   Salpietro, Stefania ^a   Gianotti, Nicola ^a   Cossarini, Francesca ^a   Carbone, Alessia ^a,b   Nozza, Silvia ^a   Bossolasco, Simona ^a   Bigoloni, Alba ^a   Lazzarin, Adriano ^a,b   Castagna, Antonella ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

AIDS defining malignancies; Cancer; HIV; HMG CoA reductase; Non AIDS defining malignancies; Risk; Statins

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; ANTIRETROVIRUS AGENT; HYPOCHOLESTEROLEMIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL THERAPY; ANUS CANCER; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; COHORT ANALYSIS; DRUG EFFECT; DRUG USE; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; ITALY; KAPOSI SARCOMA; LIVER CELL CARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; SKIN CANCER; URINARY TRACT CANCER; UTERINE CERVIX CANCER; COMPLICATION; HIV INFECTIONS; INCIDENCE; ISOLATION AND PURIFICATION; MIDDLE AGED; NEOPLASMS; RISK ASSESSMENT; VIROLOGY;

ADULT; ANTI-RETROVIRAL AGENTS; ANTICHOLESTEREMIC AGENTS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; ITALY; MALE; MIDDLE AGED; NEOPLASMS; RISK ASSESSMENT;

EID: 84916211392     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000443     Document Type: Article

References (44)

1. Spano J, Costagliola D, Katlama C, Mounier N, Oksenhendler E, Khayat D. AIDS-related malignancies: state of the art and therapeutic challenges. J Clin Oncol 2008;26:4834-4842.
2. Deeks S, Phillips A. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009;338:288-292.
3. Silverberg M, Abrams D. AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral era. Curr Opin Oncol 2007;19:446-451.
4. Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, et al. for the HIV/AIDS Cancer Match Study. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006;20:1645-1654.
5. Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008;123:187-194.
6. Crum-Cianflone N, Hullsiek K, Marconi V, Weintrob A, Ganesan A, Barthel RV, et al. Trends in the incidence of cancers among HIV-1 infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS 2009;23:41-50.
7. Deeken JF, Tien-A-Looi A, Rudek MA, Okuliar C, Young M, Little RF, et al. The rising challenge of non-AIDS-defining cancers in HIV-infected patients. Clin Infect Dis 2012;55:1228-1235.
8. Guiguet M, Bouè F, Cadranel J, Lang J-M, Rosenthal E, Costagliola D, on behalf of the Clinical Epidemiology Group of the FHDH-ANRS CO4 cohort. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 2009;10:1152-1159.
9. Biggar R, Jaffe E, Goedert J, Chaturvedi A, Pfeiffer R, Engels EA. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 2006;108:3786-3791.
10. Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol 2008;214:231-241.
11. Deeks SG. Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. Top HIV Med 2009;17:118-123.
12. Borges AH, Silverberg MJ, Wentworth D, Grulich AE, Fätkenheurer G, Mitsuyasu R, et al. Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers. AIDS 2013;27:1433-1441.
13. Tenorio A, Zheng Y, Bosch R, Deeks S, Rodrigues B, Krishnan S, et al. Soluble markers of inflammation and coagulation, but not T-cell activation, predict non-AIDS-defining events during suppressive antiretroviral therapy [Abstract R-206 (NWCS329)]. Conference on Retroviruses and Opportunistic Infections; 3-6 March 2013; Atlanta, GA.
14. McComsey GA, Kitch D, Sax PE, Tierney C, Jahed NC, Melbourne K, et al. Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS Clinical Trials Groups A5224s, a substudy of ACTG A5202. J Acquir Immune Defic Syndr 2014;65:167-174.
15. Casey PJ. Protein lipidation in cell signaling. Science 1995;268:221-225.
16. Boss JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-4689.
17. Nielsen SF, Nordestgaard BG, Bojeseb SE. Statin use and reduced cancer-related mortality. N Engl J Med 2012;367:1792-1802.
18. Tsan YT, Lee CH, Ho WC, Lin MH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. J Clin Oncol 2013;31:1514-1521.
19. Lai SW, Liao KF, Lai HC, Muo CH, Sung FC, Chen PC. Statin use and risk of hepatocellular carcinoma. Eur J Epidemiol 2013;28:485-492.
20. Lustman A, Nakar S, Cohen AD, Vinker S. Statin use and incident prostate cancer risk: does the statin brand matter? A population-based cohort study. Prostate Cancer Prostatic Dis 2014;17:6-9.
21. Beales IL, Hensley A, Loke Y. Reduced esophageal cancer incidence in statin users, particularly with cyclo-oxygenase inhibition. World J Gastrintest Pharmacol Ther 2013;4:69-79.
22. Lavie O, Pinchev M, Rennert HS, Segev Y, Rennert G. The effect of statins on risk and survival of gynaecological malignancies. Gynecol Oncol 2013;130:615-619.
23. Moore RD, Bartlett JG, Gallant JE. Association between use of HMG-CoA reductase inhibitors and mortality in HIV-1 infected patients. PLoS One 2011;6:e21843.
24. Chao C, Xu L, Abrams DI, Towner WJ, Horberg MA, Leyden WA, et al. HMG-CoA reductase inhibitors (statins) use and risk of non-Hodgkin lymphoma in HIV-positive persons. AIDS 2011;25:1771-1777.
25. Overton ET, Kitch D, Benson CA, Hunt PW, Stein JH, Smurzynski M, et al. The effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death. Clin Infect Dis 2013;56:1471-1479.
26. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992;41:01-19.
27. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
28. Mainous AG III, Wells BJ, Koopman RJ, Everett CJ, Gill JM. Iron, lipids and risk of cancer in the Framingham offspring cohort. Am J Epidemiol 2005;161:1115-1122.
29. Vilchez JA, Martinez-Ruiz A, Sancho-Rodriguez N, Martínez-Hernández P, Noguera-Velasco JA. The real role of prediagnostic high-density lipoprotein cholesterol and the cancer risk: a concise review. Eur J Clin Invest 2014;44:103-114.
30. Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, et al. 27-hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science 2013;342:1094-1098.
31. Jafri H, Alsheikh-Ali AA, Karas RH. Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy. J Am Coll Cardiol 2010;55:2846-2854.
32. Ganesan A, Crum-Cianflone N, Higgins J, Qin J, Rehm C, Metcalf J, et al. High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis 2011;203:756-764.
33. Prosperi M C F, Cozzi-Lepri A, Castagna A, Mussini C, Murri R, Giacometti A, et al., for the Icona Foundation Study Group. Incidence of malignancies in HIV infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study. Clin Infect Dis 2010;50:1316-1321.
34. Hindler K, Cleeland C, Rivera E, Collard C. The role of statins in cancer therapy. Oncologist 2006;11:306-315.
35. Niessner A, Steiner S, Speidl WS, Pleiner J, Seidinger D, Maurer G, et al. Simvastatin suppresses endotoxin-induced upregulation of toll-like receptors 4 and 2 in vivo. Atherosclerosis 2006;189:408-413.
36. Iwasaki A. Innate immune recognition of HIV-1. Immunity 2012;37:389-398.
37. Funderburg NT, Jiang Y, Debanne SM, Storer N, Labbato D, Clagett B, et al. Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy. Clin Infect Dis 2014;58:588-595.
38. Dubrow R, Silverberg MJ, Park LS, Crothers K, Justice AC, et al. HIV infection, aging, and immune function: implications for cancer risk and prevention. Curr Opin Oncol 2012;24:506-516.
39. Kesselring A, Gras L, Smit C, van Twillert G, Verbon A, de Wolf F, et al. Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy. Clin Infect Dis 2011;52:458-465.
40. Brown EE, Whitby DD, Vitale F, Marshall V, Mbisa G, Gamache C, et al. Virologic, hematologic, and immunologic risk factors for classic Kaposi sarcoma. Cancer 2006;107:2282-2290.
41. Moyle G. Anaemia in persons with HIV infection: prognostic marker and contributor to morbidity. AIDS Rev 2002;4:13-20.
42. Albini L, Calabresi A, Gotti D, Ferraresi A, Festa A, Donato F, et al. Burden of non AIDS-defining and non-virus related cancers among HIV-1 infected patients in ART era. AIDS Res Hum Retroviruses 2013;29:1097-1104.
43. Calabresi A, Ferraresi A, Festa A, Scarcella C, Donato F, Vassallo F, et al. Incidence of AIDS-defining cancers and virus-related and nonvirus-related non-AIDS-defining cancers among HIV-1 infected patients compared with the general population in a large health district of northern Italy, 1999-2009. HIV Med 2013;14:481-490.
44. Franzetti M, Adorni F, Parravicin C, Vergani B, Antinori S, Milazzo L, et al. Trends and predictors of Non AIDS-defining cancer in men and women with HIV infection. A single institution retrospective study before and after the introduction of HAART. J Acquir Immune Defic Syndr 2012;62:414-420.